Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 595 • 2014 ACR/ARHP Annual Meeting
Radiographic Sacroiliitis Progression in an Early Axial Spondyloarthritis Cohort
Concepcion Castillo-Gallego¹, Jesus Sanz², Carmen Martin-Hervas³, Mireia Moreno⁴, Victoria Navarro-Compán⁵, Diana Peiteado¹, Jorge Gratacos-Masmitja⁶, Eugenio De Miguel⁷ and Emilio Martín-Mola¹, ¹Rheumatology, Hospital La Paz - IdiPaz, Madrid, Spain, ²Rheumatology, Hospital Puerta de Hierro Majadahonda, Madrid, Spain, ³Radiology, Hospital Universitario La Paz, Madrid, Spain, ⁴Rheumatology, University Hospital Parc Taulí, Sabadell, Spain, ⁵Rheumatology, Rheumatologist, Madrid, Spain, ⁶Parc Tauli, S/N, Hospital Parc Tauli, Sabadell, Spain, ⁷Department of Rheumatology, Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: The current concept of axial Spondyloarhtritis (axSpA) considers non-radiographic axSpA (nr-axSpA) and Ankylosing Spondylitis (AS) as two stages of one disease. There are limited…
Abstract Number: 543 • 2014 ACR/ARHP Annual Meeting
Disease Activity and Clinical Response Early in the Course of Treatment Predict Long-Term Outcomes in Axial Spondyloarthritis Patients Treated with Certolizumab Pegol
Désirée M. van der Heijde¹, Atul A. Deodhar², Owen Davies³, Tommi Nurminen⁴ and Martin Rudwaleit⁵, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Arthritis and Rheumatic diseases, Oregon Health and Science University, Portland, OR, ³UCB Pharma, Slough, United Kingdom, ⁴UCB Pharma, Monheim, Germany, ⁵Endokrinologikum, Berlin, Germany
Background/Purpose: Early response to anti-TNF therapy has been shown to be a strong predictor of good long-term outcomes in ankylosing spondylitis (AS).1 However, early identification…
Abstract Number: 2830 • 2014 ACR/ARHP Annual Meeting
Progression to and Type of Orthopaedic Surgery in Juvenile Vs. Adult-Onset Ankylosing Spondylitis
Deepak R. Jadon¹, Gavin Shaddick², Amelia Jobling³, Athimalaipet V Ramanan⁴ and Raj Sengupta¹, ¹Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Department of Mathematics, University of Bath, Bath, United Kingdom, ³Department of Mathematical Sciences, University of Bath, Bath, United Kingdom, ⁴Paediatric Rheumatology, University of Bristol Hospital Trust, Bristol, United Kingdom
Background/Purpose: Juvenile-onset ankylosing spondylitis (JoAS) and adult-onset ankylosing spondylitis (AoAS) are subtypes of ankylosing spondylitis (AS) that may have different clinical outcome. We compared cohorts…
Abstract Number: 2567 • 2014 ACR/ARHP Annual Meeting
Vascular Endothelial Growth Factor and C-Reactive Protein Serum Levels Lack Predictive Value for Radiographic and Magnetic Resonance Imaging Outcomes in Patients with Active Ankylosing Spondylitis Treated with the Tumor Necrosis Factor-Inhibitor Golimumab
Xenofon Baraliakos¹, Kay-Geert A. Hermann², Stephen Xu³, Benjamin Hsu³ and Jürgen Braun¹, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Radiology, Charité Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany, ³Janssen Research & Development, LLC., Spring House, PA
Background/Purpose Using data from GO-RAISE, we analyzed correlations between serum vascular endothelial growth factor (VEGF) and C-reactive protein (CRP) levels, radiographic progression and inflammation as…
Abstract Number: 1519 • 2014 ACR/ARHP Annual Meeting
Implementation of an Acid Dissociation Procedure for Immunogenicity Detection in Patients Treated with ANTI-TNF Drugs
Francisca Llinares-Tello¹, Jose Rosas², José M. Senabre-Gallego³, Gregorio Santos-Soler³, Carlos Santos-Ramirez⁴, Esteban Salas-Heredia³, Xavier Barber⁵, Juan Molina¹, Catalina Cano³, Ana Pons³ and Group Aire-MB³, ¹Laboratory, Hospital Marina Baixa, Villajoyosa, Spain, ²Rheumatology, Hospital Marina Baixa. Villajoyosa, Villajoyosa, Spain, ³Rheumatology, Hospital Marina Baixa, Villajoyosa, Spain, ⁴Rheumatology, Hospital Marina Salud, Denia, Spain, ⁵Universidad Miguel Hernández, CIO, Elche, Spain
Background/Purpose To evaluate the application of an acid dissociation procedure in monitoring patients with subtherapeutic serum concentrations of infliximab (IFX), adalimumab (ADL) and etanercept (ETN),…
Abstract Number: 593 • 2014 ACR/ARHP Annual Meeting
The Clinimetric Outcomes of Two Bath Ankylosing Spondyltis Metrology Indices in Treatment with TNF-á Blockers
Eon Jeong Nam¹, Jeong Soo Eun², Sang Hoon Kwon³ and Young Mo Kang⁴, ¹Division of Rheumatology, Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, South Korea, ²Internal Medicine (Rheumatology), Kyungpook National University School of Medicine, Daegu, South Korea, ³Internal medicine (Rheumatology), Kyungpook National University School of Medicine, Daegu, South Korea, ⁴Dept of Internal Medicine, Kyungpook National Univ Hosp, Daegu, South Korea
Background/Purpose Bath Ankylosing Spondyltis Metrology Index (BASMI) was developed to quantify the accurate axial status and to assess the clinical changes in spinal movement. The…
Abstract Number: 538 • 2014 ACR/ARHP Annual Meeting
Secukinumab, a Monoclonal Antibody to Interleukin-17A, Significantly Improves Physical Function and Quality of Life in Subjects with Active Ankylosing Spondylitis: Results of a Phase 3 Randomized, Placebo-Controlled Trial with Intravenous Loading and Subcutaneous Maintenance Dosing
Atul A. Deodhar¹, Dominique L. Baeten², Jürgen Braun³, Xenofon Baraliakos³, Joachim Sieper⁴, Maxime Dougados⁵, Paul Emery⁶, Brian Porter⁷, Ruvie Martin⁷, Shephard Mpofu⁸ and Hanno Richards⁹, ¹Oregon Health and Sciences University, Portland, OR, ²Department of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Centre/University of Amsterdam, Amsterdam, Netherlands, ³Rheumazentrum Ruhrgebiet, Herne, Germany, ⁴Charité Universitätsmedizin Berlin, Berlin, Germany, ⁵Descartes University, Cochin Hospital, Paris, France, ⁶University of Leeds, Leeds, United Kingdom, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸Novartis Pharma AG, Basel, Switzerland, ⁹Clinical Immunology / Dermatology, Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Ankylosing spondylitis (AS) can have a profound negative effect on an individual's physical functioning, health status and quality of life (QoL), affecting the ability…
Abstract Number: 2831 • 2014 ACR/ARHP Annual Meeting
Development of New Radiographic Vertebral Fractures in Patients with Ankylosing Spondylitis during 4 Years of TNF-α Blocking Therapy: Results from the Glas Cohort
Fiona Maas¹, Anneke Spoorenberg^1,2, Elisabeth Brouwer³, Reinhard Bos², Rizwana N. Chaudhry¹, Freke Wink², Hendrika Bootsma⁴, Eveline van der Veer⁵ and Suzanne Arends^2,4, ¹Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ²Rheumatology, Medical Center Leeuwarden, Leeuwarden, Netherlands, ³Dept. of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁴Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ⁵Laboratory Medicine, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Previous studies have shown that the risk of vertebral fractures is increased in patients with ankylosing spondylitis (AS). Prospective longitudinal data about radiographic vertebral…
Abstract Number: 2562 • 2014 ACR/ARHP Annual Meeting
The Comparative One-Year Drug Survival Rate of Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid arthritis and ankylosing spondylitis; results from Turkbio Registry
Ismail Sari¹, Umut Kalyoncu², Ahmet Mesut Onat³, Omer Nuri Pamuk⁴, Omer Karadag², Bunyamin Kisacik³, Niels Steen Krogh⁵, Soner Şenel⁶, Fatih Saritaş⁷, Ihsan Ertenli², Sedat Kiraz², Pinar Cetin¹, Fatos Onen¹ and Nurullah Akkoc¹, ¹Rheumatology, Dokuz Eylul University School of Medicine, Izmir, Turkey, ²Rheumatology, Hacettepe University School of Medicine, Ankara, Turkey, ³Rheumatology, Gaziantep University School of Medicine, Gaziantep, Turkey, ⁴Department of Rheumatology, Trakya University School of Medicine, Edirne, Turkey, ⁵Consultant, ZiteLab Aps, Copenhagen, Denmark, ⁶Rheumatology, Erciyes University School of Medicine, Kayseri, Turkey, ⁷Rheumatology, Trakya University School of Medicine, Edirne, Turkey
Background/Purpose Three different anti–tumor necrosis factor α (anti-TNFα) drugs (infliximab, etanercept, and adalimumab) are approved for patients with rheumatoid arthritis (RA) and particular ankylosing spondylitis…
Abstract Number: 1367 • 2014 ACR/ARHP Annual Meeting
Cardiovascular Morbidity and Associated Risk Factors in Spanish Patients with Chronic Inflammatory Rheumatic Diseases Attending Rheumatology Clinics
Santos Castañeda¹, Maria Auxiliadora Martin², Carlos González-Juanatey³, Javier Llorca⁴, María Jesús García Yébenes⁵, Sabina Pérez-Vicente⁶, Jesús Sánchez Costa², Federico Diaz-Gonzalez⁷, Miguel A. González-Gay⁸ and CARMA Project Collaborative Group⁵, ¹Rheumatology, Hospital Universitario de La Princesa, IISP, Madrid, Spain, ²Unidad de Investigación, Sociedad Española de Reumatología, Madrid, Spain, ³Hospital Universitario Lucus Augusti. Cardiology Division, Lugo, Spain, ⁴Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), Santander, Spain, ⁵Sociedad Española de Reumatología, Madrid, Spain, ⁶Unidad de Investigación de la Sociedad Española de Reumatología, Madrid, Spain, ⁷Rheumatology, Servicio de Reumatologia.Hospital Universitario de Canarias, La Laguna, Spain, ⁸Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain
Background/Purpose: The prevalence of cardiovascular disease (CVD) in chronic inflammatory rheumatic diseases (CIRD) is higher than in the general population. Recent studies have emphasized that…
Abstract Number: 591 • 2014 ACR/ARHP Annual Meeting
The Fat Spondyloarthritis Spine Score (FASSS) Independently Predicts Radiographic Progression in Patients with Ankylosing Spondylitis
Susanne Juhl Pedersen¹, Stephanie Wichuk², Praveena Chiowchanwisawakit³, Zheng Zhao⁴, Robert GW Lambert⁵ and Walter P. Maksymowych⁶, ¹Copenhagen Center for Arthritis Research, Copenhagen University Hospital at Glostrup, Copenhagen, Denmark, ²Department of Medicine, University of Alberta, Edmonton, AB, Canada, ³Mahidol University, Bangkok, Thailand, ⁴PLA General Hospital, Beijing, China, ⁵Radiology, University of Alberta, Edmonton, AB, Canada, ⁶Medicine/Rheumatic Dis Unit, University of Alberta, Edmonton, AB, Canada
The Fat Spondyloarthritis Spine Score (FASSS) independently predicts radiographic progression in patients with ankylosing spondylitis. Background/Purpose Vertebral corner fat lesions have been shown to be…
Abstract Number: 536 • 2014 ACR/ARHP Annual Meeting
Secukinumab, a Monoclonal Antibody to Interleukin-17A, Significantly Improves Signs and Symptoms of Active Ankylosing Spondylitis: Results of a Phase 3, Randomized, Placebo-Controlled Trial with Subcutaneous Loading and Maintenance Dosing
Joachim Sieper¹, Jürgen Braun², Xenofon Baraliakos², Dominique L. Baeten³, Maxime Dougados⁴, Paul Emery⁵, Atul A. Deodhar⁶, Brian Porter⁷, Mats Andersson⁸, Shephard Mpofu⁸ and Hanno Richards⁹, ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²Rheumazentrum Ruhrgebiet, Herne, Germany, ³Department of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Centre/University of Amsterdam, Amsterdam, Netherlands, ⁴INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France., Paris, France, ⁵University of Leeds, Leeds, United Kingdom, ⁶Oregon Health and Sciences University, Portland, OR, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸Novartis Pharma AG, Basel, Switzerland, ⁹Clinical Immunology / Dermatology, Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Previous data indicate that interleukin (IL)-17, a key pro-inflammatory cytokine, might play a role in the pathogenesis of ankylosing spondylitis (AS). We assessed the…
Abstract Number: 2832 • 2014 ACR/ARHP Annual Meeting
The Effect of Co-Medication with Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs on TNF Inhibitor Drug Survival in Patients with Ankylosing Spondylitis: Results from a Nationwide Prospective Study
Elisabeth Lie^1,2, Lars Erik Kristensen³, Helena Forsblad-d'Elia¹, Johan Askling⁴ and Lennart T. Jacobsson¹, ¹Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, ²Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Section of Rheumatology, Department of Clinical Sciences, Lund University, Malmö, Sweden, ⁴Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden
Background/Purpose For rheumatoid arthritis it is well established that co-medication (co-med) with methotrexate (MTX) increases the efficacy and drug survival of TNF inhibitors (TNFi), while…
Abstract Number: 2564 • 2014 ACR/ARHP Annual Meeting
Ileocolonoscopic Findings in the Korean Patients with Ankylosing Spondylitis
Soo Min Ahn, Bin Yoo, Chang-Keun Lee, Yong-Gil Kim, Seokchan Hong, Seung-Hyeon Bae and Doo-Ho Lim, Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea
Background/Purpose: The prevalence of concurrent Ankylosing spondylitis (AS) and inflammatory bowel disease, either Crohn's disease (CD) or Ulcerative colitis (UC), is estimated at 5-10%. Up…
Abstract Number: 1285 • 2014 ACR/ARHP Annual Meeting
Prevalence of Risk Factors for Gastrointestinal Side Effects of Drugs for the Treatment of Pain in Rheumatic Diseases and the Provision of Gastroprotective Treatment – Results of a Large Non-Intervention Study
Gustavo Citera¹, Edgardo Smecuol², Alberto Millán³, Manuel Robles⁴ and Ruben Mantilla⁵, ¹Universidad de Buenos Aires, Buenos Aires, Argentina, ²Hospital Municipal de Gastroenterología, Buenos Aires, Argentina, ³Hospital Universitario de Caracas, Caracas, Venezuela, ⁴Centro Médico Toluca, Toluca, Mexico, ⁵Clínica de Artritis y Rehabilitación (CAYRE), Bogota, Colombia
Background/Purpose: Non-steroidal anti-inflammatory drugs (NSAIDs) are the long established first-line treatment for the management of pain associated with rheumatic diseases but carry a risk of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].